Alto Neuroscience ANRO Convertible Debt - Current
Convertible Debt - Current at other companies
Other financials
Where this comes from
Reported directly by Alto Neuroscience in its filing.
Tagged under the XBRL concept us-gaap:ConvertibleDebt.
The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alto Neuroscience's convertible debt - current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alto Neuroscience's convertible debt - current?
- Alto Neuroscience (ANRO) reported convertible debt - current of $2.34M in Q1 2026.
- How has Alto Neuroscience's convertible debt - current changed year-over-year?
- Alto Neuroscience's convertible debt - current increased by 92.8% year-over-year, from $1.21M to $2.34M.
- What is the long-term trend for Alto Neuroscience's convertible debt - current?
- Over 3 years (2022 to 2025), Alto Neuroscience's convertible debt - current has grown at a -68.6% compound annual growth rate (CAGR), from $72.24M to $2.23M.
- What does convertible debt - current mean?
- This represents the portion of a company's total convertible debt obligations that is scheduled to mature or become due within the next twelve months. It serves as a critical indicator of near-term liquidity requirements and potential dilution risk, as these instruments may be settled in cash or converted into equity upon maturity. Monitoring this balance is essential for assessing a clinical-stage biopharmaceutical company's short-term capital structure and its ability to manage upcoming debt obligations without disrupting research and development activities.